R&D | December 12, 2025
OTR Therapeutics and Zealand Pharma join forces to target metabolic diseases
The companies aim to expand treatment options for millions living with metabolic disorders
The companies aim to expand treatment options for millions living with metabolic disorders
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
The company had achieved the highest "A" rating in Climate Change
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
It's an acquisition that aims at forming one of the US's largest oncology trial networks
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Subscribe To Our Newsletter & Stay Updated
